Healthcare & Pharma

Zipalertinib Hits Primary Endpoint in Lung Cancer Trial as Biotech Catalyst Season Delivers Mixed Reads

Positive pivotal data in EGFR exon 20 lung cancer lands alongside Definium's Phase 3 Voyage topline in generalized anxiety disorder and a dense slate of clinical-stage earnings calls from Allogene and Inovio.

Zipalertinib met its primary endpoint in a lung cancer study, delivering a clean pivotal readout into an unusually crowded biotech catalyst window that also featured Definium Therapeutics' Phase 3 Voyage results for DT120 and quarterly updates from Allogene and Inovio.

Analyst Desks Fan Out Across Biotech and Consumer as China Auto Demand Cracks

A heavy slate of target revisions from Guggenheim, Canaccord and UBS spans oncology, energy and household products, even as a 20% collapse in Chinese passenger vehicle retail sales flags a genuine demand shock in the world's largest auto market.

Sell-side research activity clustered in clinical-stage biotech and consumer discretionary names, with upgrades for ConocoPhillips, SharkNinja, BridgeBio and Cogent offset by reductions at Middleby and Neurogene. The sharper signal came from China, where July passenger vehicle retail sales fell 20% year over year.

Insider Selling Cluster Spans Industrials, MedTech and Mobility in Single Session

Executives at ICU Medical, AZZ, CSW Industrials, Lyft and Miami International Holdings disclosed dispositions totalling several million dollars — much of it under Rule 10b5-1 plans, but the breadth of the pattern warrants attention.

A notably broad cluster of insider sales crossed the wire covering ICU Medical (COO $1.63m, director $68,978), AZZ (president and COO $647,981), CSW Industrials ($249,811), Lyft (director $241,740), Beta Technologies (CEO $1.15m) and Miami International Holdings ($137,370). While many transactions were pre-scheduled under Rule 10b5-1 plans, the concentration across unrelated sectors in a single session is a signal worth monitoring on valuation grounds.

AbCellera jumps 22% on positive trial data

The antibody discovery company's shares rose sharply after it reported favourable clinical trial results.